Medlab Clinical (ASX:MDC) Equity-to-Asset : -1.86 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Medlab Clinical Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Medlab Clinical's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$-0.70 Mil. Medlab Clinical's Total Assets for the quarter that ended in Dec. 2023 was A$0.38 Mil. Therefore, Medlab Clinical's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -1.86.

The historical rank and industry rank for Medlab Clinical's Equity-to-Asset or its related term are showing as below:

ASX:MDC' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.86 Med: 0.73 Max: 0.95
Current: -1.86

During the past 8 years, the highest Equity to Asset Ratio of Medlab Clinical was 0.95. The lowest was -1.86. And the median was 0.73.

ASX:MDC's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.67 vs ASX:MDC: -1.86

Medlab Clinical Equity-to-Asset Historical Data

The historical data trend for Medlab Clinical's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlab Clinical Equity-to-Asset Chart

Medlab Clinical Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Equity-to-Asset

Get a 7-Day Free Trial

0.75

0.64

0.73

0.71

0.41

Medlab Clinical Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial												0.76	0.71	0.50	0.41	-1.86

Competitive Comparison of Medlab Clinical's Equity-to-Asset

For the Biotechnology subindustry, Medlab Clinical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medlab Clinical's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medlab Clinical's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Medlab Clinical's Equity-to-Asset falls into.

Medlab Clinical Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Medlab Clinical's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	1.28	/	3.144
	=	0.41

Medlab Clinical's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-0.701	/	0.377
	=	-1.86

Medlab Clinical (ASX:MDC) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Medlab Clinical Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Medlab Clinical's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Medlab Clinical (ASX:MDC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (ASX:MDC) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Lord Street, Unit 5, Botany, NSW, AUS, 2019

Website

https://www.medlab.co

Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.